Neptune Technologies & Bioressources Inc. (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc. and Acasti Pharma Inc. Its Neptune produces and commercializes nutraceutical products. Its Acasti Pharma Inc. develops and commercializes pharmaceutical applications for cardiovascular diseases. Its NeuroBioPharm Inc. develops and commercializes pharmaceutical applications for neurological diseases. It produces omega-3 PUFAs through its patented process of extracting oils from Antartic krill, which omega-3 PUFAs are then principally sold as bulk oil to Neptune's distributors who commercialize them under their private label primarily in the United States, European and Australian nutraceutical markets. The Company's products include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKO).
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: CVE:NTB
- CUSIP: N/A
- Web: N/A
Capitalization:- Market Cap: C$116.92 million
- Outstanding Shares: 77,945,000
Average Prices:- 50 Day Moving Avg: C$2.00
- 200 Day Moving Avg: C$1.00
- 52 Week Range: C$77,945,000.00 - C$1.08
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0
Frequently Asked Questions for Neptune Technologies & Bioressources (CVE:NTB)
What is Neptune Technologies & Bioressources' stock symbol?
Neptune Technologies & Bioressources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NTB."
How were Neptune Technologies & Bioressources' earnings last quarter?
Neptune Technologies & Bioressources Inc (CVE:NTB) posted its quarterly earnings results on Tuesday, July, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The company earned $3.69 million during the quarter, compared to the consensus estimate of $7.31 million. View Neptune Technologies & Bioressources' Earnings History.
When will Neptune Technologies & Bioressources make its next earnings announcement?
Who are some of Neptune Technologies & Bioressources' key competitors?
Some companies that are related to Neptune Technologies & Bioressources include Copper Mountain Mining Co.. (CMMC), Input Capital Corp (INP), BSM Technologies (GPS), Conifex Timber (CFF), Orezone Gold Corp (ORE), Titanium Co. (TIC), Madalena Energy (MVN), Strategic Oil & Gas Ltd (SOG), Pan Orient Energy Corp. (POE), Canamax Energy Ltd (CAC), Atico Mining Corp (ATY), Mosaic Capital Corp (M), Ikkuma Resources Corp (IKM), Luna Gold Corp (LGC), Atacama Pacific Gold (ATM), Africa Energy Corp (AFE), C-Com Satellite Systems (CMI) and Orosur Mining (OMI).
How do I buy Neptune Technologies & Bioressources stock?
Shares of Neptune Technologies & Bioressources and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Neptune Technologies & Bioressources' stock price today?
One share of Neptune Technologies & Bioressources stock can currently be purchased for approximately C$1.50.
MarketBeat Community Rating for Neptune Technologies & Bioressources (CVE NTB)MarketBeat's community ratings are surveys of what our community members think about Neptune Technologies & Bioressources and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Neptune Technologies & Bioressources (CVE:NTB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Neptune Technologies & Bioressources (CVE:NTB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Neptune Technologies & Bioressources (CVE:NTB)Earnings History by Quarter for Neptune Technologies & Bioressources (CVE NTB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/11/2017 | | | | | | | | |
| 7/15/2014 | | C($0.08) | C($0.06) | C$7.31 million | C$3.69 million | View | N/A |  |
| 5/21/2014 | | C($0.08) | C($0.08) | C$6.36 million | C$3.67 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Neptune Technologies & Bioressources (CVE:NTB)Current Year EPS Consensus Estimate: $0.02 EPS
Dividend History for Neptune Technologies & Bioressources (CVE:NTB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Neptune Technologies & Bioressources (CVE:NTB)Insider Trades by Quarter for Neptune Technologies & Bioressources (CVE:NTB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/1/2016 | James Stuart Hamilton | Director | Buy | 4,000 | C$1.58 | C$6,320.00 | |
| 1/28/2016 | James Stuart Hamilton | Director | Buy | 2,000 | C$1.55 | C$3,100.00 | |
| 1/18/2016 | Mario Paradis | Insider | Buy | 10,000 | C$1.50 | C$15,000.00 | |
| 1/15/2016 | John Morris Moretz | Director | Buy | 700,651 | C$1.05 | C$735,683.55 | |
| 1/15/2016 | Mario Paradis | Insider | Buy | 40,000 | C$1.54 | C$61,672.00 | |
| 10/29/2015 | John Morris Moretz | Director | Buy | 26,044 | C$1.08 | C$28,101.48 | |
| 10/28/2015 | John Morris Moretz | Director | Buy | 24,500 | C$1.12 | C$27,538.00 | |
| 10/27/2015 | John Morris Moretz | Director | Buy | 5,500 | C$1.09 | C$6,006.00 | |
| 10/23/2015 | John Morris Moretz | Director | Buy | 50,000 | C$1.17 | C$58,385.00 | |
| 10/5/2015 | John Morris Moretz | Director | Buy | 13,692 | C$1.24 | C$16,991.77 | |
| 10/2/2015 | John Morris Moretz | Director | Buy | 33,900 | C$1.23 | C$41,663.10 | |
| 9/15/2015 | John Morris Moretz | Director | Buy | 9,001 | C$1.24 | C$11,161.24 | |
| 7/22/2015 | John Morris Moretz | Director | Buy | 2,800 | C$1.34 | C$3,750.60 | |
| 7/21/2015 | John Morris Moretz | Director | Buy | 21,654 | C$1.34 | C$28,975.22 | |
| 7/16/2015 | Pierre Lemieux | Director | Sell | 6,250 | C$1.62 | C$10,135.00 | |
| 6/8/2015 | Pierre Fitzgibbon | Director | Buy | 47,500 | C$1.70 | C$80,693.00 | |
| 2/17/2015 | Reed Tuckson | Director | Buy | 10,800 | C$1.85 | C$19,931.40 | |
| 2/13/2015 | Michel Timperio | Insider | Sell | 10,000 | C$2.19 | C$21,870.00 | |
| 2/6/2015 | André Godin | Insider | Sell | 5,000 | C$2.14 | C$10,700.00 | |
| 2/5/2015 | Michel Timperio | Insider | Sell | 15,000 | C$2.11 | C$31,680.00 | |
| 1/30/2015 | Bel Dominique Le | Insider | Sell | 15,000 | C$2.30 | C$34,500.00 | |
| 1/29/2015 | Bel Dominique Le | Insider | Sell | 10,000 | C$2.25 | C$22,500.00 | |
| 1/22/2015 | Claudie Lauzon | Insider | Sell | 8,334 | C$2.04 | C$16,966.36 | |
| 1/22/2015 | Pierre Lemieux | Director | Sell | 11,250 | C$2.00 | C$22,500.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Neptune Technologies & Bioressources (CVE:NTB)
Latest Headlines for Neptune Technologies & Bioressources (CVE:NTB)
| Source: |
|
Neptune Technologies & Bioressources (NTB) Chart for Sunday, September, 24, 2017
